Header Logo

Marta Batus

Concepts (147)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Sarcoma
9
2023
142
2.570
Why?
Lung Neoplasms
15
2024
505
1.980
Why?
Antineoplastic Agents
8
2016
176
1.850
Why?
Carcinoma, Non-Small-Cell Lung
14
2024
216
1.690
Why?
Soft Tissue Neoplasms
2
2022
55
0.910
Why?
Molecular Targeted Therapy
3
2013
33
0.880
Why?
Metastasectomy
1
2021
7
0.780
Why?
Antibodies, Monoclonal
4
2016
192
0.740
Why?
Bone Neoplasms
3
2022
118
0.740
Why?
Immunotherapy
3
2021
48
0.710
Why?
Antineoplastic Combined Chemotherapy Protocols
6
2019
224
0.650
Why?
Direct-to-Consumer Advertising
1
2016
1
0.540
Why?
Medical Oncology
1
2016
40
0.510
Why?
Chemoradiotherapy
4
2019
61
0.490
Why?
Retrospective Studies
16
2023
3297
0.470
Why?
Prognosis
9
2023
750
0.450
Why?
ErbB Receptors
4
2018
51
0.440
Why?
Melanoma
1
2013
48
0.420
Why?
Neoplasm Staging
11
2024
313
0.370
Why?
Humans
28
2024
26025
0.360
Why?
Survival Rate
5
2021
321
0.300
Why?
Mutation
3
2021
311
0.290
Why?
Carcinoma, Squamous Cell
4
2018
160
0.270
Why?
Neutrophils
2
2023
96
0.240
Why?
Female
17
2024
14397
0.240
Why?
Male
16
2024
14008
0.230
Why?
Body Composition
1
2024
61
0.230
Why?
Drug Resistance, Neoplasm
2
2018
61
0.230
Why?
Neoplasm Recurrence, Local
2
2016
185
0.230
Why?
Middle Aged
12
2024
8507
0.220
Why?
Receptor, IGF Type 1
2
2013
17
0.210
Why?
Quinazolines
2
2012
13
0.200
Why?
Sarcoma, Synovial
1
2022
11
0.200
Why?
High-Throughput Nucleotide Sequencing
1
2021
43
0.190
Why?
Pneumonectomy
1
2021
67
0.190
Why?
Antineoplastic Agents, Immunological
1
2021
15
0.180
Why?
Adenocarcinoma
3
2018
123
0.180
Why?
Lung
1
2021
155
0.180
Why?
Autoantibodies
1
2021
71
0.180
Why?
Treatment Outcome
8
2021
3292
0.170
Why?
Biomarkers, Tumor
1
2021
179
0.160
Why?
Erlotinib Hydrochloride
1
2018
10
0.150
Why?
Aged
11
2024
8704
0.150
Why?
Inflammation Mediators
1
2018
58
0.150
Why?
Survival Analysis
5
2021
235
0.140
Why?
Palliative Care
2
2015
104
0.140
Why?
Adult
7
2022
7363
0.140
Why?
Protein Kinase Inhibitors
2
2018
45
0.120
Why?
Neoplasm Metastasis
2
2013
93
0.120
Why?
Gene Dosage
2
2012
16
0.120
Why?
Biomarkers
1
2018
549
0.120
Why?
Radiotherapy, Conformal
1
2014
14
0.110
Why?
Cancer Vaccines
1
2013
5
0.110
Why?
Angiogenesis Inhibitors
1
2013
15
0.110
Why?
Neoplasms
1
2016
219
0.110
Why?
Forecasting
1
2013
91
0.110
Why?
Follow-Up Studies
5
2018
1712
0.100
Why?
Weight Gain
1
2012
61
0.100
Why?
PTEN Phosphohydrolase
1
2011
6
0.100
Why?
Positron Emission Tomography Computed Tomography
2
2022
27
0.100
Why?
Fluorodeoxyglucose F18
2
2022
38
0.100
Why?
Phosphatidylinositol 3-Kinases
1
2011
40
0.100
Why?
Child, Preschool
1
2013
589
0.100
Why?
Adolescent
2
2016
2064
0.090
Why?
Young Adult
2
2016
1853
0.090
Why?
Body Weight
2
2024
121
0.090
Why?
Gene Amplification
1
2010
18
0.090
Why?
Pyrimidines
1
2010
20
0.090
Why?
Xanthine Dehydrogenase
1
2010
6
0.090
Why?
Rectal Neoplasms
1
2010
11
0.090
Why?
United States
1
2016
1981
0.090
Why?
Lymphocytes
2
2023
59
0.090
Why?
Gastrointestinal Stromal Tumors
1
2010
29
0.090
Why?
Gene Expression Regulation, Neoplastic
1
2010
95
0.080
Why?
Piperazines
1
2010
76
0.080
Why?
Clinical Trials as Topic
1
2010
215
0.080
Why?
Child
1
2013
1228
0.080
Why?
Lymphohistiocytosis, Hemophagocytic
1
2008
9
0.080
Why?
Animals
2
2013
3389
0.080
Why?
Chromosomes, Human, Pair 3
1
2007
4
0.070
Why?
Chromosomes, Human, Pair 10
1
2007
5
0.070
Why?
Chromosomes, Human, Pair 1
1
2007
7
0.070
Why?
Receptor, ErbB-2
1
2007
47
0.070
Why?
Carcinoma, Large Cell
2
2018
12
0.070
Why?
Prospective Studies
2
2023
1659
0.060
Why?
Neoadjuvant Therapy
2
2019
63
0.060
Why?
Kaplan-Meier Estimate
2
2017
161
0.060
Why?
Aged, 80 and over
4
2018
4659
0.060
Why?
Etoposide
2
2015
25
0.060
Why?
Carboplatin
2
2015
23
0.060
Why?
Paclitaxel
2
2015
42
0.060
Why?
Lymphocyte Count
1
2023
16
0.050
Why?
Tumor Microenvironment
1
2023
16
0.050
Why?
Breast Neoplasms
1
2007
353
0.050
Why?
Body Mass Index
1
2024
412
0.050
Why?
Margins of Excision
1
2022
27
0.050
Why?
Time-to-Treatment
1
2022
32
0.050
Why?
Radiopharmaceuticals
1
2022
49
0.050
Why?
Positron-Emission Tomography
1
2022
84
0.050
Why?
B7-H1 Antigen
1
2021
9
0.050
Why?
Programmed Cell Death 1 Receptor
1
2021
14
0.050
Why?
Antigens, Neoplasm
1
2021
38
0.050
Why?
Observer Variation
1
2021
93
0.050
Why?
Cohort Studies
2
2015
1823
0.040
Why?
Patient Selection
1
2021
193
0.040
Why?
Mesna
1
2019
3
0.040
Why?
Ifosfamide
1
2019
13
0.040
Why?
Organ Sparing Treatments
1
2019
7
0.040
Why?
Leg
1
2019
48
0.040
Why?
Doxorubicin
1
2019
54
0.040
Why?
Arm
1
2019
80
0.040
Why?
Tomography, X-Ray Computed
2
2014
713
0.040
Why?
Time Factors
1
2022
1365
0.040
Why?
Proteomics
1
2018
90
0.040
Why?
Leukocyte Count
1
2017
64
0.030
Why?
Bevacizumab
1
2016
20
0.030
Why?
Taxoids
1
2016
8
0.030
Why?
Deoxycytidine
1
2016
20
0.030
Why?
Pemetrexed
1
2015
4
0.030
Why?
Radiation Pneumonitis
1
2015
3
0.030
Why?
Hemoptysis
1
2015
7
0.030
Why?
Esophagitis
1
2015
6
0.030
Why?
Cough
1
2015
9
0.030
Why?
Chest Pain
1
2015
19
0.030
Why?
Chemoradiotherapy, Adjuvant
1
2015
14
0.030
Why?
Radiation Injuries
1
2015
25
0.030
Why?
Dyspnea
1
2015
37
0.030
Why?
Disease-Free Survival
1
2015
158
0.030
Why?
Mobility Limitation
1
2015
94
0.030
Why?
Radiotherapy Dosage
1
2014
93
0.030
Why?
Radiotherapy Planning, Computer-Assisted
1
2014
55
0.030
Why?
Diet
1
2015
169
0.030
Why?
Class I Phosphatidylinositol 3-Kinases
1
2011
10
0.020
Why?
Activities of Daily Living
1
2015
522
0.020
Why?
Immunohistochemistry
1
2012
335
0.020
Why?
Imatinib Mesylate
1
2010
8
0.020
Why?
Benzamides
1
2010
15
0.020
Why?
Colectomy
1
2010
17
0.020
Why?
Combined Modality Therapy
1
2011
277
0.020
Why?
Quality of Life
1
2015
609
0.020
Why?
Signal Transduction
1
2012
389
0.020
Why?
Biopsy
1
2010
199
0.020
Why?
Smoking
1
2010
169
0.020
Why?
Risk Assessment
1
2011
622
0.020
Why?
Fatal Outcome
1
2008
50
0.020
Why?
Trastuzumab
1
2007
25
0.020
Why?
Antibodies, Monoclonal, Humanized
1
2007
87
0.020
Why?
Batus's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (147)
Explore
_
Co-Authors (22)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_